News & Updates

Show Multimedia Only

First-line methotrexate on par with prednisone for sarcoidosis

18 Jun 2025 by

The use of methotrexate as a first line of treatment for patients with pulmonary sarcoidosis delivers similar efficacy to prednisone as measured by forced vital capacity after 24 weeks, results of the PREDMETH trial have shown.

First-line methotrexate on par with prednisone for sarcoidosis

18 Jun 2025

Inclisiran superior to ezetimibe in LDL-C reduction in patients without ASCVD

18 Jun 2025

Treatment with inclisiran monotherapy demonstrates good tolerability and better reduction in low-density lipoprotein cholesterol (LDL-C) levels when compared with ezetimibe and placebo in patients without atherosclerotic cardiovascular disease (ASCVD), reports a study.

Inclisiran superior to ezetimibe in LDL-C reduction in patients without ASCVD

18 Jun 2025

RSV-ARI nearly triples mortality risk in new study

18 Jun 2025 by

Acute respiratory infection caused by respiratory syncytial virus (RSV-ARI) nearly triples the risk of death, particularly among individuals with chronic underlying respiratory conditions, as shown in a nationwide cohort study in Denmark.

RSV-ARI nearly triples mortality risk in new study

18 Jun 2025

Adalimumab delivers consistent benefit in plaque psoriasis, with or without methotrexate

18 Jun 2025

Treatment outcomes with adalimumab for plaque psoriasis appear to be similar between patients on monotherapy and those receiving concomitant methotrexate, according to the BSTOP study.

Adalimumab delivers consistent benefit in plaque psoriasis, with or without methotrexate

18 Jun 2025

Ferric carboxymaltose infusion offers little help in iron-deficient patients with heart failure

17 Jun 2025

Intravenous ferric carboxymaltose does not appear to be beneficial in terms of heart failure (HF) hospitalization and cardiovascular mortality in patients with HF and iron deficiency, according to a study.

Ferric carboxymaltose infusion offers little help in iron-deficient patients with heart failure

17 Jun 2025

Glucose-lowering med shows promise for treating kidney stones in nondiabetics

17 Jun 2025 by

Treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin helps improve the urinary lithogenic risk profile of nondiabetic patients with calcium and uric acid stones, as shown in the results of the randomized crossover SWEETSTONE trial.

Glucose-lowering med shows promise for treating kidney stones in nondiabetics

17 Jun 2025

GLP-1 RAs reduce depression, substance use in young patients with obesity, MASLD

17 Jun 2025 by

In paediatric patients with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), treatment with GLP-1 receptor agonists (RAs) results in a decrease in depression and substance use, as shown in a study presented at ESPGHAN 2025.

GLP-1 RAs reduce depression, substance use in young patients with obesity, MASLD

17 Jun 2025

Oveporexton demonstrates therapeutic potential in narcolepsy type 1

17 Jun 2025

Treatment with the investigational oral orexin receptor 2–selective agonist oveporexton appears to yield improvements in wakefulness, sleepiness, and cataplexy in individuals with narcolepsy type 1, according to the results of a phase II study.

Oveporexton demonstrates therapeutic potential in narcolepsy type 1

17 Jun 2025

Fremanezumab tackles migraine, depression at the same time

16 Jun 2025 by

Fremanezumab appears to provide a two-for-one benefit in patients with migraine and comorbid depressive disorder, with data from the UNITE study showing that the drug helped reduce migraine days and lift mood.

Fremanezumab tackles migraine, depression at the same time

16 Jun 2025

SGLT2i extends survival in amyloidosis patients with or without HF

16 Jun 2025 by

Treatment with SGLT2 inhibitors can prolong the life of patients with amyloidosis with or without a diagnosis of heart failure (HF), a study has shown.

SGLT2i extends survival in amyloidosis patients with or without HF

16 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

First-line methotrexate on par with prednisone for sarcoidosis

First-line methotrexate on par with prednisone for sarcoidosis

Inclisiran superior to ezetimibe in LDL-C reduction in patients without ASCVD

Inclisiran superior to ezetimibe in LDL-C reduction in patients without ASCVD

RSV-ARI nearly triples mortality risk in new study

RSV-ARI nearly triples mortality risk in new study

Adalimumab delivers consistent benefit in plaque psoriasis, with or without methotrexate

Adalimumab delivers consistent benefit in plaque psoriasis, with or without methotrexate

Ferric carboxymaltose infusion offers little help in iron-deficient patients with heart failure

Ferric carboxymaltose infusion offers little help in iron-deficient patients with heart failure

Glucose-lowering med shows promise for treating kidney stones in nondiabetics

Glucose-lowering med shows promise for treating kidney stones in nondiabetics

GLP-1 RAs reduce depression, substance use in young patients with obesity, MASLD

GLP-1 RAs reduce depression, substance use in young patients with obesity, MASLD

Oveporexton demonstrates therapeutic potential in narcolepsy type 1

Oveporexton demonstrates therapeutic potential in narcolepsy type 1

Fremanezumab tackles migraine, depression at the same time

Fremanezumab tackles migraine, depression at the same time

SGLT2i extends survival in amyloidosis patients with or without HF

SGLT2i extends survival in amyloidosis patients with or without HF